$NOVO B #Novo Nordisk A/S B Novo Nordisk : Second positive trial for semaglutide in obesity: &gt;STEP 1 shows weight loss of over 15kg in 68 weeks - Novo Nordisk announced new positive phase III results for semaglutide (once-a-week GLP-1) in… https://t.co/yWkA4a3CwK #equity #stocks https://t.co/bZT0FMTy7K